Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
2Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Gain Therapeutics, Inc. (GANX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
7Total relationships
1Distinct source URLs
4High confidence
0.797Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Gain Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MINORYX-THERAPEUTICS-SL
MINORYX-THERAPEUTICS-SL
92%
In December 2017, the Company entered into an exclusive worldwide, royalty-bearing, assignable, transferable license agreement with Minoryx to use and exploit Minoryx’s intellectual property
Reciprocal relationship from ALEC graph: Reciprocal relationship from GANX graph: Reciprocal relationship from ALEC graph: Reciprocal relationship from GANX graph: Reciprocal relationship from ALEC g…
Gain Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
, as compared to $40 thousand for the three months ended March 31, 2025. The increase was mainly attributable to higher interest income from a higher balance in our money market fund over the compara…
Reciprocal relationship from CRS graph: Reciprocal relationship from GANX graph: , as compared to $40 thousand for the three months ended March 31, 2025. The increase was mainly attributable to highe…
Gain Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
GANX-DEBT-9714
Warrants outstanding: 200000
90%
xbrl warrant detail from xbrl 2025-12-31.
GANX-DEBT
Debt stack $343,686
90%
Market cache reports total debt of $343,686.
Gain Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Gain Therapeutics, Inc..
Gain Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
GANX-OWNER-MARSHALL-WACE-LLP
MARSHALL WACE, LLP
90%
13F overlay lists MARSHALL WACE, LLP as top holder; 43 tracked holders.
Gain Therapeutics, Inc. Extended Supply Chain Network